At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
18F-DCFBCdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Mar 21, 2013·Updated Aug 20, 2018
In Brief
A Phase 2 clinical trial evaluating 18F-DCFBC for Metastatic Prostate Cancer. Completed, enrolled 22 participants across 1 site.
Detailed Summary
This research is being done to see if an investigational radioactive drug called 18F-DCFBC can help us find cancer that has spread (metastatic disease) from its original site in people who have cancer in their prostate to other parts of their body.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Prostate Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2013
First PostedMar 2013
Primary CompletionJul 2015
Study CompletionNov 2015
TodayJul 2026
First PostedMar 21, 2013
Enrollment StartMar 1, 2013
Primary CompletionJul 1, 2015
Study CompletionNov 18, 2015
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.3 years ago
Interventions
18F-DCFBCdrug
18F-DCFBC is a radiofluorinated small-molecule inhibitor of prostate-specific membrane antigen (PSMA). A bolus of 10 mCi (370 MBq) \[9-11 mCi (333-407 MBq)\] of 18F-DCFBC will be injected into the IV line by slow IV push.